Explore the words cloud of the NanoFEITH project. It provides you a very rough idea of what is the project "NanoFEITH" about.
The following table provides information about the project.
Coordinator |
UNIVERSITY OF CYPRUS
Organization address contact info |
Coordinator Country | Cyprus [CY] |
Total cost | 151˙648 € |
EC max contribution | 151˙648 € (100%) |
Programme |
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility) |
Code Call | H2020-MSCA-IF-2017 |
Funding Scheme | MSCA-IF-EF-ST |
Starting year | 2018 |
Duration (year-month-day) | from 2018-06-01 to 2020-05-31 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | UNIVERSITY OF CYPRUS | CY (NICOSIA) | coordinator | 151˙648.00 |
Breast cancer (BC) represents a leading cause of cancer-related death in women worldwide, in large part due to ineffective detection and treatment. Nanotechnology offers new promise in mitigating BC mortality, by combining therapy with early diagnosis in “theranostic” nanoparticles (NPs). Here, a multidisciplinary approach is proposed to develop and evaluate novel theranostic NPs, which for the first time combine near infrared (NIR) metal-enhanced fluorescence (MEF) imaging with multimodal cancer treatment. MEF is a promising strategy for dramatically improving the low fluorescent signals of available NIR dyes, but limited MEF platforms for in vivo applications have been developed. Here, elongated gold (Au) NPs (nanobipyramids) with two sharp tips and tunable sizes/optical properties are expected to provide distinct advantages, including large fluorescence enhancement and increased tumour accumulation, thus enabling real-time in vivo imaging with high sensitivity and spatial resolution. Furthermore, BC photothermal therapy by the Au core will be combined with a chemotherapeutic drug-carrier surface coating, bearing pH-responsive lids to allow controlled drug and Zn ion release at the tumour site. Coordinated use of these modalities is expected to minimize systemic side effects, improve therapeutic efficacy and be useful in treating drug resistant tumours. Several complementary techniques, including computational modelling, 3D in vitro cell cultures, in vivo testing and advanced 3D imaging will be combined to characterize NP biodistribution, biocompatibility and passive vs. active tumour targeting. These will provide vital insights for the – still challenging – clinical translation of NPs in general, paving the way toward personalized nanomedicine. The proposed research/training will complement the Applicant’s skills in materials science with the Host’s expertise in cancer drug delivery to enhance his professional maturity and promote international collaborations.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NANOFEITH" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "NANOFEITH" are provided by the European Opendata Portal: CORDIS opendata.